Blood Res.  2013 Mar;48(1):67-67. 10.5045/br.2013.48.1.67.

Many questions raised by a question on JAK1/2 inhibitors in primary myelofibrosis

Affiliations
  • 1Institute of Haematology and Transfusion Medicine, KPC Medical College & Hospital, India. lalitraut76@yahoo.co.in

Abstract

No abstract available.


MeSH Terms

Primary Myelofibrosis

Reference

1. Jung CW. Will JAK1/2 inhibitors change the standard of care for myelofibrosis? Korean J Hematol. 2012; 47:241–242. PMID: 23319999.
Article
2. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366:799–807. PMID: 22375971.
Article
Full Text Links
  • BR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr